Ray Therapeutics
Last verified 2026-05-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $200.0Mattributed |
|---|---|
| Latest round | series-b, $125.0M, 2026-04-24attributed |
| Founded | 2018 |
| Headquarters | San Francisco |
| Industry | bio |
| Stage | series-b+ |
| Website | raytherapeutics.com |
Ray Therapeutics develops optogenetic gene therapies for degenerative retinal diseases, reprogramming surviving retinal neurons to sense light and signal the brain. It targets patients with blinding conditions such as retinitis pigmentosa and Stargardt disease. Rather than replacing damaged cells, it repurposes neurons that remain after disease.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-24 | series-b | $125.0M | undisclosed |
Detected tech stack
Cloudflare, Typekit, Adobe Fonts, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, Elementor 3.28.3, DoubleClick Floodlight, Cloudflare Bot Management, WP Engine, WPMU DEV Smush 3.23.1, Python
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $125.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $200.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | raytherapeutics.com, read 2026-05-13 |
| Description | self-reported | raytherapeutics.com, read 2026-05-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.